flecainide has been researched along with Heart Failure in 35 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide." | 9.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "Two infants with chaotic atrial tachycardia diagnosed at birth and at 11 weeks of life, were treated successfully with oral flecainide." | 7.68 | Successful treatment of chaotic atrial tachycardia with oral flecainide. ( Davignon, A; Fournier, A; Houyel, L, 1990) |
| "The trough concentration-dose (C/D) ratio of flecainide was prospectively studied in 78 patients with various cardiac arrhythmias." | 7.68 | Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone. ( Coumel, P; Denjoy, I; Leclercq, JF; Mentré, F, 1990) |
| "In 42 patients with heart failure who were on long-term treatment with flecainide (2 X 100 mg daily by mouth) plasma concentration of flecainide was measured before the morning dose and compared with the clinical grade of heart failure or left ventricular ejection fraction (in the levo-angiogram)." | 7.67 | [Elevated plasma flecainide concentrations in heart failure]. ( Köhler, U; Lüderitz, B; Neyses, L; Nitsch, J, 1987) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 7.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure." | 7.67 | Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure. ( Dijk, A; Dunselman, PH; Kingma, JH; Lie, KI; van Wijk, LM; Wesseling, H, 1985) |
| " During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it." | 6.66 | Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. ( , 1988) |
| "In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation." | 5.11 | Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. ( Alboni, P; Baldi, N; Baroffio, R; Botto, GL; Calzolari, M; Gaggioli, G; Gianfranchi, L; Luzi, M; Marchi, P; Russo, V; Solano, A, 2004) |
| "In this study we investigated the time to the first arrhythmic, ischemic, or failure event for encainide-flecainide and moricizine versus their respective placebo comparison groups in the Cardiac Arrhythmia Suppression Trial." | 5.08 | Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. ( Anderson, JL; Carlson, M; Davies, R; Duff, HJ; Greene, HL; Hallstrom, AP; Huther, M; Kammerling, JM; Romhilt, DW, 1995) |
| "There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide." | 5.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "Patients randomized to placebo in the encainide and flecainide arms of the Cardiac Arrhythmia Suppression Trial (CAST) have been found to have a relatively low 1-year mortality rate of 3." | 5.07 | Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. ( Capone, RJ; el-Sherif, N; Geraci, TS; Handshaw, K; Morganroth, J; Pawitan, Y; Schlant, RC; Waldo, AL, 1991) |
| "High-dose flecainide and digoxin combination offers effective treatment strategy in fetuses with hydrops and tachyarrhythmia with favourable outcomes." | 4.12 | Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review. ( Beattie, RB; Tunca Sahin, G; Uzun, O, 2022) |
| "We report a case of fetal supraventricular tachycardia with intra uterine cardiac failure, treated with oral administration of flecainide acetate (Flecaine) to the mother." | 3.69 | [Flecaine: drug of choice for supraventricular tachycardias with anasarca. A case report]. ( Barjot, P; Febbraro, W; Hamel, P; Iselin, M; Lindet, Y; Muller, G, 1997) |
| "Two infants with chaotic atrial tachycardia diagnosed at birth and at 11 weeks of life, were treated successfully with oral flecainide." | 3.68 | Successful treatment of chaotic atrial tachycardia with oral flecainide. ( Davignon, A; Fournier, A; Houyel, L, 1990) |
| "The trough concentration-dose (C/D) ratio of flecainide was prospectively studied in 78 patients with various cardiac arrhythmias." | 3.68 | Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone. ( Coumel, P; Denjoy, I; Leclercq, JF; Mentré, F, 1990) |
| "Flecainide has unusual electrophysiologic properties and a high potency for the suppression of ventricular tachyarrhythmias." | 3.67 | Effects of flecainide on ventricular function: clinical and experimental correlations. ( Ikeda, N; Josephson, MA; Singh, BN, 1984) |
| "Seventy-six patients with ventricular tachyarrhythmias (40 sustained and 36 nonsustained) were treated with oral flecainide." | 3.67 | Influence of left ventricular dysfunction on flecainide therapy. ( de Paola, AA; Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Senior, S; Spielman, SR, 1987) |
| "In 42 patients with heart failure who were on long-term treatment with flecainide (2 X 100 mg daily by mouth) plasma concentration of flecainide was measured before the morning dose and compared with the clinical grade of heart failure or left ventricular ejection fraction (in the levo-angiogram)." | 3.67 | [Elevated plasma flecainide concentrations in heart failure]. ( Köhler, U; Lüderitz, B; Neyses, L; Nitsch, J, 1987) |
| " This study assessed in 1,330 patients followed up for 292 +/- 393 days the predictive value for cardiovascular safety of a system by which patients were classified according to ventricular arrhythmias on entry, presence or absence of organic heart disease and drug dose for flecainide acetate." | 3.67 | Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. ( Anderson, JL; Gentzkow, GD; Morganroth, J, 1986) |
| "The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure." | 3.67 | Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure. ( Dijk, A; Dunselman, PH; Kingma, JH; Lie, KI; van Wijk, LM; Wesseling, H, 1985) |
| "Baseline data from the Cardiac Arrhythmia Suppression Trial were used to define several categories of heart failure and to relate both the resulting categories and ejection fraction to arrhythmia suppression and mortality using logistic and survival regression analytic methodologies." | 2.68 | Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. ( DeMaria, A; Gottlieb, S; Greene, HL; Hallstrom, A; Huther, M; Pratt, CM; Young, JB, 1995) |
| " During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it." | 2.66 | Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. ( , 1988) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "The nature of an arrhythmia and of individual patient factors change over time, requiring a flexible approach to long-term treatment that may be defined only after months or years." | 2.39 | Atrial fibrillation: maintenance of sinus rhythm versus rate control. ( Camm, AJ; Sopher, SM, 1996) |
| " For patients with ventricular premature complexes, the half-life is longer (mean 20 hours), and twice-daily oral dosage is effective." | 2.37 | Metabolism of flecainide. ( Conard, GJ; Ober, RE, 1984) |
| " On the other hand, the elimination half-life of antiarrhythmic agents that have a large volume of distribution and are highly cleared by the liver may be twice as long in patients with CHF compared with normal subjects." | 2.37 | Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. ( Echt, DS; Roden, DM; Woosley, RL, 1986) |
| "Pharmacological management of cardiac arrhythmia has failed because it is not possible to predict how drugs that target cardiac ion channels, and have intrinsically complex dynamic interactions with ion channels, will alter the emergent electrical behavior generated in the heart." | 1.37 | A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms. ( Bankston, JR; Bayer, JD; Christini, DJ; Clancy, CE; Jeng, MT; Kang, C; Kass, RS; Moreno, JD; Ripplinger, CM; Trayanova, NA; Wang, L; Yang, PC; Zhu, ZI, 2011) |
| "Congestive heart failure was more common in all amiodarone and sotalol users as well as past users of flecainide." | 1.36 | Rhythm control agents and adverse events in patients with atrial fibrillation. ( Hobbs, FD; Hodgkinson, J; Taylor, CJ, 2010) |
| "Tachycardia was finally controlled with flecainide while the patient was on left ventricular assist device support." | 1.33 | Successful treatment of tachycardia-induced cardiomyopathy with LVAD in a 12-year-old boy. ( Kaji, Y; Masuda, M; Morita, S; Nishida, T; Tatewaki, H; Ushinohama, H; Yasui, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (40.00) | 18.7374 |
| 1990's | 12 (34.29) | 18.2507 |
| 2000's | 3 (8.57) | 29.6817 |
| 2010's | 4 (11.43) | 24.3611 |
| 2020's | 2 (5.71) | 2.80 |
| Authors | Studies |
|---|---|
| Tunca Sahin, G | 1 |
| Beattie, RB | 1 |
| Uzun, O | 1 |
| Hagino, M | 1 |
| Ota, C | 1 |
| Onoki, T | 1 |
| Iwasawa, S | 1 |
| McKenzie, GA | 1 |
| Porter, B | 1 |
| Kaprielian, R | 1 |
| Lip, GY | 1 |
| Fauchier, L | 2 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Taylor, CJ | 1 |
| Hodgkinson, J | 1 |
| Hobbs, FD | 1 |
| Moreno, JD | 1 |
| Zhu, ZI | 1 |
| Yang, PC | 1 |
| Bankston, JR | 1 |
| Jeng, MT | 1 |
| Kang, C | 1 |
| Wang, L | 1 |
| Bayer, JD | 1 |
| Christini, DJ | 1 |
| Trayanova, NA | 1 |
| Ripplinger, CM | 1 |
| Kass, RS | 1 |
| Clancy, CE | 1 |
| Naccarelli, GV | 1 |
| Wolbrette, DL | 1 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Alboni, P | 1 |
| Botto, GL | 1 |
| Baldi, N | 1 |
| Luzi, M | 1 |
| Russo, V | 1 |
| Gianfranchi, L | 1 |
| Marchi, P | 1 |
| Calzolari, M | 1 |
| Solano, A | 1 |
| Baroffio, R | 1 |
| Gaggioli, G | 1 |
| Tatewaki, H | 1 |
| Masuda, M | 1 |
| Nishida, T | 1 |
| Kaji, Y | 1 |
| Ushinohama, H | 1 |
| Morita, S | 1 |
| Yasui, H | 1 |
| Conard, GJ | 1 |
| Ober, RE | 1 |
| Josephson, MA | 1 |
| Ikeda, N | 1 |
| Singh, BN | 1 |
| Breithardt, G | 1 |
| Borggrefe, M | 1 |
| Yeh, HL | 1 |
| Seipel, L | 1 |
| Hallstrom, AP | 2 |
| Anderson, JL | 2 |
| Carlson, M | 1 |
| Davies, R | 1 |
| Greene, HL | 4 |
| Kammerling, JM | 1 |
| Romhilt, DW | 1 |
| Duff, HJ | 1 |
| Huther, M | 2 |
| Hallstrom, A | 1 |
| Pratt, CM | 1 |
| Gottlieb, S | 1 |
| DeMaria, A | 1 |
| Young, JB | 1 |
| Greenberg, HM | 1 |
| Dwyer, EM | 1 |
| Hochman, JS | 1 |
| Steinberg, JS | 1 |
| Echt, DS | 4 |
| Peters, RW | 2 |
| Sopher, SM | 1 |
| Camm, AJ | 1 |
| Hamel, P | 1 |
| Febbraro, W | 1 |
| Barjot, P | 1 |
| Lindet, Y | 1 |
| Muller, G | 1 |
| Iselin, M | 1 |
| Azancot-Benisty, A | 1 |
| Areias, JC | 1 |
| Oberhänsli, I | 1 |
| Schmidt, KG | 1 |
| Tulzer, G | 1 |
| Viart, P | 1 |
| Babuty, D | 1 |
| Autret, ML | 1 |
| Poret, P | 1 |
| Cosnay, P | 1 |
| Fauchier, JP | 1 |
| Tuinenburg, AE | 1 |
| Van Gelder, IC | 1 |
| Van Den Berg, MP | 1 |
| Brügemann, J | 1 |
| De Kam, PJ | 1 |
| Crijns, HJ | 1 |
| Liebson, PR | 1 |
| Mitchell, LB | 1 |
| Obias-Manno, D | 1 |
| Barker, AH | 2 |
| Arensberg, D | 1 |
| Baker, A | 1 |
| Friedman, L | 1 |
| Capone, RJ | 2 |
| Pawitan, Y | 1 |
| el-Sherif, N | 1 |
| Geraci, TS | 1 |
| Handshaw, K | 1 |
| Morganroth, J | 3 |
| Schlant, RC | 1 |
| Waldo, AL | 1 |
| Houyel, L | 1 |
| Fournier, A | 1 |
| Davignon, A | 1 |
| Leclercq, JF | 1 |
| Denjoy, I | 1 |
| Mentré, F | 1 |
| Coumel, P | 1 |
| Richardson, DW | 1 |
| McBride, R | 1 |
| Roden, DM | 2 |
| Gottlieb, SS | 1 |
| Szatmáry, LJ | 1 |
| Bernadet, P | 1 |
| Puel, P | 1 |
| Mikloweit, P | 1 |
| Bienmüller, H | 1 |
| Woosley, RL | 1 |
| de Paola, AA | 1 |
| Horowitz, LN | 1 |
| Senior, S | 1 |
| Spielman, SR | 1 |
| Greenspan, AM | 1 |
| Kay, HR | 1 |
| Nitsch, J | 1 |
| Neyses, L | 1 |
| Köhler, U | 1 |
| Lüderitz, B | 1 |
| Cavalli, A | 1 |
| Maggioni, AP | 1 |
| Marchi, S | 1 |
| Volpi, A | 1 |
| Latini, R | 1 |
| Gentzkow, GD | 1 |
| Dunselman, PH | 1 |
| Kingma, JH | 1 |
| van Wijk, LM | 1 |
| Dijk, A | 1 |
| Wesseling, H | 1 |
| Lie, KI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [NCT00000504] | Phase 2 | 0 participants | Interventional | 1982-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
5 reviews available for flecainide and Heart Failure
| Article | Year |
|---|---|
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Metabolism of flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Biotransformation; Blood Proteins; Chromatography, High Pressure Li | 1984 |
Atrial fibrillation: maintenance of sinus rhythm versus rate control.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calc | 1996 |
Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Digitalis; Disopyramide; Drug Interactions; Encainide; | 1986 |
9 trials available for flecainide and Heart Failure
| Article | Year |
|---|---|
Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
Topics: Administration, Oral; Ambulatory Care; Anti-Arrhythmia Agents; Atrial Fibrillation; Feasibility Stud | 2004 |
Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Flecainide; Heart Fail | 1995 |
Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial.
Topics: Arrhythmias, Cardiac; Electrocardiography; Encainide; Female; Flecainide; Heart Failure; Humans; Mal | 1995 |
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Drug Interactio | 1995 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square Distribution; Double-Blind Method; En | 1991 |
Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study).
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Double-Blind Method; Encainide; Fema | 1989 |
The use of antiarrhythmic agents in heart failure: implications of CAST.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecain | 1989 |
Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Metho | 1988 |
21 other studies available for flecainide and Heart Failure
| Article | Year |
|---|---|
Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cesarean Section; Digoxin; Female; Fetal Diseases; Fle | 2022 |
Male infant with Noonan syndrome with
Topics: Amiodarone; Arrhythmias, Cardiac; Cardiomyopathy, Hypertrophic; Flecainide; Heart Failure; Humans; I | 2022 |
An 89-year-old man presents with worsening heart failure.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Disease Progression; Electrocardiography; Flecainide; Hea | 2016 |
Rhythm control agents and adverse events in patients with atrial fibrillation.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Case-Control Studies; Female; | 2010 |
A computational model to predict the effects of class I anti-arrhythmic drugs on ventricular rhythms.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Computer Simulation; Flecainide; Heart Conduc | 2011 |
Successful treatment of tachycardia-induced cardiomyopathy with LVAD in a 12-year-old boy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Child; Flecainide; Heart Failure; Heart-Assist Devices; Hu | 2005 |
Effects of flecainide on ventricular function: clinical and experimental correlations.
Topics: Adult; Aged; Animals; Anti-Arrhythmia Agents; Cardiac Catheterization; Coronary Disease; Female; Fle | 1984 |
[Electrophysiological effects of flecainide on stimulus-inducible ventricular tachycardia].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiograp | 1982 |
[Flecaine: drug of choice for supraventricular tachycardias with anasarca. A case report].
Topics: Anti-Arrhythmia Agents; Electrocardiography; Female; Fetal Diseases; Flecainide; Heart Failure; Huma | 1997 |
[European protocol for the management of fetal supraventricular tachycardia. European Association of Pediatric Cardiology].
Topics: Anti-Arrhythmia Agents; Digoxin; Drug Therapy, Combination; Electrocardiography; Female; Fetal Death | 1997 |
Effect of flecainide on heart rate variability in subjects without coronary artery disease or congestive heart failure.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Coronary Disease; Electrocardiography; Female; Flec | 1998 |
Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Electric Countershock | 1999 |
Successful treatment of chaotic atrial tachycardia with oral flecainide.
Topics: Administration, Oral; Electrocardiography; Flecainide; Heart Atria; Heart Failure; Humans; Infant; I | 1990 |
Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodarone.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Body Weight; Dose-Response Relationship, Drug; Drug I | 1990 |
Mechanical circulatory assistance in the management of patients in coronary care unit.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Cardiac Surgical Procedures; | 1988 |
[Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril].
Topics: Aged; Cholestasis, Intrahepatic; Drug Therapy, Combination; Enalapril; Female; Flecainide; Heart Fai | 1987 |
Influence of left ventricular dysfunction on flecainide therapy.
Topics: Adult; Aged; Female; Flecainide; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Stroke | 1987 |
[Elevated plasma flecainide concentrations in heart failure].
Topics: Adult; Aged; Female; Flecainide; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Time Facto | 1987 |
Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Flecainide; Half-Life; Heart Failure; Humans; Middle Aged | 1988 |
Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
Topics: Arrhythmias, Cardiac; Death, Sudden; Drug Administration Schedule; Flecainide; Heart Failure; Humans | 1986 |
Haemodynamic and antiarrhythmic effects of intravenous flecainide acetate in chronic congestive heart failure.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Electrocardiography; Flecainide; Hear | 1985 |